newsfilter
← Latest News
Business Wire·

NeoGenomics Reports Second Quarter 2026 Results

Total revenue increased 11% YoY to $202 million Clinical services revenue grew 14%, with NGS revenue growth of 26% Company raises full-year 2026 revenue and adjusted EBITDA guidance NeoGenomics, Inc. (NASDAQ:NEO)